cidofovir anhydrous has been researched along with valganciclovir in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 3 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hoffman, VF; Skiest, DJ | 1 |
| Salmon-Ceron, D | 1 |
| Zaia, JA | 1 |
| Emery, VC; Leśnikowski, ZJ; Olejniczak, A; Paradowska, E; Przepiórkiewicz, M | 1 |
| Michaels, MG | 1 |
| Boucher, HW; Torres-Madriz, G | 1 |
| Járay, J; Péter, A; Telkes, G; Varga, M | 1 |
| Bunjes, D; Härter, G; Mertens, T; Michel, D; Schreiber, A; Schubert, A | 1 |
| Kern, ER; Prichard, MN | 1 |
| Bastide, C; Bruyère, F; Chandenier, J; Desoubeaux, G; Fourcade, C; Guy, L; Karsenty, G; Lachaud, L; Lavigne, JP; Malavaud, S; Sotto, A | 1 |
| Spencer, JF; Tollefson, AE; Toth, K; Wold, WSM; Ying, B | 1 |
| Meesing, A; Razonable, RR | 1 |
| Anderson, TK; Chien, M; Jockusch, S; Ju, J; Kirchdoerfer, RN; Kumar, S; Li, X; Russo, JJ; Tao, C | 1 |
| Blumberg, EA; Halpern-Cohen, V | 1 |
| Bowlin, TL; Hussein, ITM; Tollefson, AE; Toth, K | 1 |
12 review(s) available for cidofovir anhydrous and valganciclovir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic developments in cytomegalovirus retinitis.
Topics: Adenine; Antibodies, Monoclonal; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drugs, Investigational; Foscarnet; Ganciclovir; Guanine; Humans; Organophosphonates; Organophosphorus Compounds; Thionucleotides; Valganciclovir | 2000 |
Cytomegalovirus infection: the point in 2001.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Monitoring; Foscarnet; Ganciclovir; Humans; Organophosphonates; Organophosphorus Compounds; Polymerase Chain Reaction; Population Surveillance; Predictive Value of Tests; Prevalence; Risk Factors; Valganciclovir | 2001 |
[Drugs against human cytomegalovirus].
Topics: Acyclovir; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drugs, Investigational; Female; Foscarnet; Ganciclovir; Global Health; Humans; Infectious Disease Transmission, Vertical; Naphthalenesulfonates; Organophosphonates; Organophosphorus Compounds; Pregnancy; Pregnancy Complications, Infectious; Thionucleotides; Valacyclovir; Valganciclovir; Valine | 2002 |
Treatment of congenital cytomegalovirus: where are we now?
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Female; Foscarnet; Ganciclovir; Humans; Infant, Newborn; Organophosphonates; Pregnancy; Valganciclovir | 2007 |
Immunocompromised hosts: perspectives in the treatment and prophylaxis of cytomegalovirus disease in solid-organ transplant recipients.
Topics: Antiviral Agents; Chemoprevention; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Immunocompromised Host; Organ Transplantation; Organophosphonates; Transplantation; Valganciclovir | 2008 |
[Gastrointestinal cytomegalovirus infections in organ transplant patients].
Topics: Acyclovir; Antiviral Agents; Biopsy; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Endoscopy, Gastrointestinal; Foscarnet; Ganciclovir; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Immunocompromised Host; Immunoglobulins; Immunotherapy, Adoptive; Intestinal Mucosa; Organ Transplantation; Organophosphonates; Primary Prevention; Valganciclovir | 2008 |
Antiviral treatment of cytomegalovirus infection and resistant strains.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Resistance, Viral; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Organophosphonates; Thionucleotides; Valganciclovir | 2009 |
The search for new therapies for human cytomegalovirus infections.
Topics: Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Foscarnet; Ganciclovir; Guanine; Humans; Organophosphonates; Valganciclovir; Virus Replication | 2011 |
[Non-antibiotic anti-infectious treatments in urology].
Topics: Acyclovir; Albendazole; Amphotericin B; Anti-Infective Agents; Caspofungin; Cidofovir; Cytosine; Echinocandins; Fluconazole; Flucytosine; Foscarnet; Ganciclovir; Humans; Ivermectin; Lipopeptides; Organophosphonates; Praziquantel; Urologic Diseases; Valganciclovir | 2013 |
New Developments in the Management of Cytomegalovirus Infection After Transplantation.
Topics: Acetates; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Drug Resistance, Viral; Foscarnet; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Organ Transplantation; Quinazolines; Valganciclovir | 2018 |
New Perspectives on Antimicrobial Agents: Maribavir.
Topics: Adult; Anti-Infective Agents; Antiviral Agents; Benzimidazoles; Child; Cidofovir; Cytomegalovirus Infections; Dichlororibofuranosylbenzimidazole; Drug Resistance, Viral; Foscarnet; Ganciclovir; Humans; Valganciclovir | 2022 |
4 other study(ies) available for cidofovir anhydrous and valganciclovir
| Article | Year |
|---|---|
Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Chemoprevention; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ganciclovir; Hematopoietic Stem Cell Transplantation; Humans; Organophosphonates; Organophosphorus Compounds; Postoperative Complications; Risk Factors; Transplantation, Autologous; Transplantation, Homologous; Valacyclovir; Valganciclovir; Valine | 2002 |
HAdV-C6 Is a More Relevant Challenge Virus than HAdV-C5 for Testing Antiviral Drugs with the Immunosuppressed Syrian Hamster Model.
Topics: A549 Cells; Adenoviridae Infections; Adenovirus Infections, Human; Adenoviruses, Human; Animals; Antiviral Agents; Cell Line; Cidofovir; Cricetinae; Cytosine; Disease Models, Animal; Ganciclovir; Humans; Immunosuppression Therapy; Liver; Male; Organophosphonates; Valganciclovir; Viral Load; Virus Replication | 2017 |
A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19.
Topics: Antiviral Agents; Betacoronavirus; Cidofovir; Coronavirus Infections; COVID-19; Dideoxynucleosides; Ganciclovir; Guanine; Nucleotides; Pandemics; Pneumonia, Viral; Prodrugs; RNA-Dependent RNA Polymerase; RNA, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Stavudine; Valganciclovir | 2020 |
Filociclovir is a potent inhibitor of human adenovirus F41.
Topics: Adenoviruses, Human; Antiviral Agents; Child; Cidofovir; Ganciclovir; Humans; Valganciclovir | 2022 |